TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7750190
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment in isolated GH deficiency (GHD) group
Study: 2115156
Drug: Inhaled disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled disodium cromoglycate (DSCG) 40 mg
Study: 2115156
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol 200 micrograms
Study: 6988171
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trimebutine 3-times daily for 3 days
Study: 6988171
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trimebutine 3-times daily for 2 weeks
Study: 6988171
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mebeverine 4-times daily
Study: 31638682
Drug: Fluoxetine (n=75)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (n=75)
Study: 31638682
Drug: Fluoxetine vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine vs Placebo
Study: 20589679
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxyurea and imatinib
Study: 19526158
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion (RP‐E)
Study: 19526158
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (RP)
Study: 10450621
Drug: Cognitive-behavioral bibliotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral bibliotherapy (BT) with weekly phone consultations
Study: 321176
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg/day
Study: 321176
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg/day + Triamterene 50 mg/day
Study: 321176
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg/day + Triamterene 100 mg/day
Study: 29574635
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 50 (LM50)
Study: 20739147
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy combined with hypocaloric parenteral nutrition (HPN) including recombinant human growth hormone, octreotide, and systemic insulin
Study: 20739147
Drug: Standard total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard total parenteral nutrition and systemic insulin
Study: 19216734
Drug: Autologous cultured
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous cultured osteoblast injection
Study: 11574374
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg intrathecal morphine (MS)
Study: 11574374
Drug: 0.2 mL
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL of 0.9% saline (normal saline; NS)
Study: 9270509
Drug: Cream vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream vehicle (control)
Study: 28885479
Drug: 20% subcutaneous
Normalized name: Cuvitru, 20% subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% subcutaneous immunoglobulin (SCIG)
Study: 28885479
Drug: Individualized training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized training and support for self-infusion
Study: 25695181
Drug: Promotion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promotion of hand washing and once-weekly application of chlorhexidine-based body wash
Study: 22099273
Drug: 81 mEq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mEq per day of oral potassium-sodium citrate (27 mEq three times a day)
Study: 18337330
Drug: Flocculant-disinfectant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flocculant-disinfectant treatment
Study: 18337330
Drug: Control households
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control households (no treatment)
Study: 9003855
Drug: Deferoxamine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine administered by twice‐daily subcutaneous injections
Study: 9003855
Drug: Conventional administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional administration by prolonged subcutaneous infusion
Study: 9003855
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily dose administered as a single injection
Study: 9003855
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of deferoxamine
Study: 1488663
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (colloidal bismuth subcitrate and ampicillin)
Study: 1488663
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) therapy
Study: 1488663
Drug: Ampicillin therapy
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin therapy
Study: 3698065
Drug: One 500-mg
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 500-mg clotrimazole vaginal tablet for one day
Study: 3698065
Drug: Two 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 100-mg clotrimazole vaginal tablets daily for three days
Study: 3698065
Drug: Three-day treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day treatment group
Study: 29878043
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose (25% wt:vol, ∼1400 mOsmol/L)
Study: 29878043
Drug: Intraduodenal sucralose
Normalized name: Sucralose
DrugBank: Sucralose (DB15049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal sucralose (4 mmol/L, ∼300 mOsmol/L)
Study: 29878043
Drug: Intraduodenal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal saline (0.9% wt:vol, ∼300 mOsmol/L)
Study: 27281699
Drug: ω‐3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 supplementation (2.9 g/d)
Study: 24370819
Drug: Active motor
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active motor rehabilitation treatment based on voluntary exercises including task-oriented exercises.
Study: 20723644
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (5 g IV for 1 hour, followed by ibutilide and another 5 g for 2 additional hours)
Study: 19004414
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of MDMA (50-75 mg)
Study: 15879361
Drug: Metformin (1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1700 mg daily) for 6 months
Study: 8634167
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg/day
Study: 1323616
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg orally five times daily for 5 days after UV exposure, starting 1 day before exposure.
Study: 1323616
Drug: Matched placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo, administered similarly to acyclovir group.
Study: 28093132
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (CRO) with standard analgesia
Study: 21081908
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg once daily for 7 days)
Study: 21081908
Drug: Aspirin-phosphatidylcholine (PL2200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-phosphatidylcholine (PL2200, 325 mg once daily for 7 days)
Study: 19951570
Drug: Intensive multifactorial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multifactorial integrated therapy targeting hyperglycemia, hypertension, dyslipidemia, and aspirin
Study: 19951570
Drug: Conventional outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional outpatient treatment
Study: 17289766
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg once daily for 7 days
Study: 17289766
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg twice daily for 7 days
Study: 9828271
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg intravenous glucagon
Study: 9828271
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravenous glucagon
Study: 7214806
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravenous glucagon
Study: 9828271
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg and 0.5 mg intravenous glucagon
Study: 9828271
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg and 1 mg intravenous glucagon
Study: 1658875
Drug: Monopic porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monopic porcine insulin (proinsulin less than 10 ppm)
Study: 1658875
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (proinsulin less than 1 ppm)
Study: 1658875
Drug: Bovine insulin
Normalized name: Bovine insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine insulin (proinsulin less than 3,000 ppm)
Study: 25456420
Drug: Gamisoyo-San multi-compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamisoyo-San multi-compound extract
Study: 11932288
Drug: 0.5 mg/kg.d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg.d rhIGF-I/IGFBP-3
Study: 11932288
Drug: 1 mg/kg.d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg.d rhIGF-I/IGFBP-3
Study: 8537870
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral hygiene quadrant)
Study: 29355162
Drug: Intravenous 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.25 mg/kg dexamethasone in 5 ml solution
Study: 21284406
Drug: palonosetron 0.5
Normalized name: palonosetron 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: palonosetron 0.5 μg/kg
Study: 21284406
Drug: palonosetron 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: palonosetron 1.0 μg/kg
Study: 21284406
Drug: palonosetron 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: palonosetron 1.5 μg/kg
Study: 16234576
Drug: Hydrogel wound
Normalized name: GRx Hydrogel Wound Filler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel wound dressing containing a combination of endopeptidases
Study: 12704989
Drug: Lymphoscintigraphy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoscintigraphy and physical preventive therapy
Study: 10070130
Drug: Atropine infusion
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine infusion [0.4 mg/m2 bolus, 0.4 mg. (m2)‐1. h‐1] for 2 h
Study: 1778222
Drug: Atropine infusion
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine infusion
Study: 7737228
Drug: Diltiazem (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.1 mg.kg‐1 h‐1, n = 32)
Study: 2344229
Drug: Gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 50 mg capsules t.i.d.
Study: 2344229
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg capsules t.i.d.
Study: 29020189
Drug: Ivermectin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150 μg/kg) administered every 3 months for 3 years
Study: 29020189
Drug: Ivermectin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150 μg/kg) administered annually for 3 years
Study: 25720986
Drug: Two-piece implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-piece implants
Study: 24278914
Drug: One-piece implants
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-piece implants
Study: 19827649
Drug: Lipantil 200M
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipantil 200M (phenofibrate) 200 mg for 12 weeks
Study: 17396620
Drug: Emilok (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emilok (test formulation)
Study: 17396620
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available original preparation (reference formulation)
Study: 16285942
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (omeprazole plus amoxicillin for 5 days, followed by omeprazole plus clarithromycin plus tinidazole for another 5 days)
Study: 16285942
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole, amoxicillin, and metronidazole for 1 week)
Study: 9564988
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg orally once daily for 10 to 14 days
Study: 8770707
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (immunosuppressive drug regimen without TPEX)
Study: 2972165
Drug: remoxipride (75‐375
Approvals — FDA: no, EMA: no, PMDA: no
Description: remoxipride (75‐375 mg daily)
Study: 2972165
Drug: thioridazine (150‐750
Approvals — FDA: no, EMA: no, PMDA: no
Description: thioridazine (150‐750 mg daily)
Study: 365205
Drug: Salicylates (3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylates (3.9 g per day)
Study: 19514558
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amlodipine plus 2 mg terazosin
Study: 12198056
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 micrograms plus magnesium sulfate 50 mg
Study: 2181788
Drug: telenzepine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: telenzepine 3 mg nocte
Study: 10235195
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg nocte
Study: 6769448
Drug: Doxapram 2
Normalized name: doxapram 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 2 mg ml‐1
Study: 29047145
Drug: Patient-specific opioid
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific opioid dosing protocol
Study: 29047145
Drug: Weight-based opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based opioid dosing protocol
Study: 27496180
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy added to treatment as usual
Study: 23427393
Drug: Intravenous Xuebijing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Xuebijing plus conventional therapy (Group B)
Study: 21078806
Drug: Citalopram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram infusion (blocking SERT)
Study: 15806416
Drug: Methadone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (100 mg/day)
Study: 15806416
Drug: Buprenorphine (32.40+/‐2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (32.40+/‐2.8 mg/day)
Study: 8882755
Drug: Capsaicin applied
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin applied locally (30 microns), treatment given once a week for 5 consecutive weeks
Study: 1944720
Drug: Oral phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phosphatidylcholine at 900 mg/day for 8 weeks
Study: 6416286
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) aerosol (10 mg) before exercise
Study: 6416286
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) aerosol (10 mg) after exercise
Study: 26503077
Drug: 5 h/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 h/day CCM treatment
Study: 26503077
Drug: 12 h/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 h/day CCM treatment
Study: 24946625
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (5 times a week for 8 weeks)
Study: 22261571
Drug: N-acetylcysteine (NAC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC; 1 g/d)
Study: 22261571
Drug: Glutamine (Gln;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (Gln; 20 g/d)
Study: 19921150
Drug: Beta-lactam antibiotic
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam antibiotic regimen (weekly cycling of ceftriaxone, amoxicillin-clavulanic acid)
Study: 17391168
Drug: Repaglinide 2
Normalized name: repaglinide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 2 mg thrice daily
Study: 15755766
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance in girls with AN
Study: 9620322
Drug: Early cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early cyclosporine monotherapy
Study: 9620322
Drug: Double-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug therapy (cyclosporine and steroids)
Study: 8571077
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg per day)
Study: 2591470
Drug: Theo-Dur tablets
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theo-Dur tablets with a balanced meal
Study: 2591470
Drug: Theo-Dur tablets
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theo-Dur tablets with a hyperlipidic meal
Study: 25359159
Drug: Insulin glargine,
Normalized name: insulin glargine, human recombin. analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5 mmol/L for 24 weeks
Study: 25359159
Drug: Liraglutide, escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide, escalated to the highest approved clinical dose of 1.8 mg daily for 24 weeks
Study: 12464714
Drug: ergotamine 1
Normalized name: ergotamine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ergotamine 1 mg/caffeine 100 mg
Study: 6371285
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural analgesia with bupivacaine (0.25% or 0.125%) and morphine (3 mg injected twice a day)
Study: 6371285
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (3 mg injected twice a day)
Study: 21411613
Drug: Probiotics with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics with GOS (3.8 g/d)
Study: 21411613
Drug: Probiotics with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics with GOS and rye bread (minimum 120 g/d)
Study: 11566459
Drug: Ketoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (200 mg daily) for 1 week followed by ketoprofen (200 mg daily) and aspirin (325 mg daily)
Study: 11566459
Drug: Ketoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (200 mg daily) for 1 week followed by ketoprofen (200 mg daily) alone
Study: 11566459
Drug: Ketoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (200 mg daily) with aspirin (325 mg daily)
Study: 11566459
Drug: Ketoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (200 mg daily) without aspirin
Study: 7825702
Drug: Functional meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional meal preparation group (n = 23)
Study: 3373080
Drug: Dapsone (DDS)
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone (DDS) injection
Study: 3373080
Drug: Monoacetyldapsone (MADDS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoacetyldapsone (MADDS) injection
Study: 29024079
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5% gel or cream
Study: 16574999
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of cisplatin in course 1
Study: 16574999
Drug: BSA-adjusted dose
Normalized name: Fmlt bsasm h
DrugBank: Honokiol (DB19283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSA-adjusted dose of cisplatin in course 2
Study: 15389743
Drug: Actual laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual laser therapy (LLLT)
Study: 19876045
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy
Study: 3817031
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (high doses, orally administered)
Study: 31114155
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of amlodipine 10 mg/olmesartan 40 mg/rosuvastatin 20 mg
Study: 31114155
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of FDC (amlodipine 10 mg/olmesartan 40 mg) and rosuvastatin 20 mg